STOCK TITAN

PolyPid to Present at the Barclays Global Healthcare Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences

PETACH TIKVA, Israel, March 07, 2023 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD), (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it will present at the Barclays Global Healthcare Conference, which is being held in Miami, Florida, on March 14-16, 2023.

Barclays Global Investor Conference:

Presentation Date: Tuesday, March 14, 2023
Presentation Time:4:35 PM Eastern Time
  

Investors interested in meeting with PolyPid during the conference should contact their Barclays representative.

About PolyPid
PolyPid Ltd. (Nasdaq: PYPD) is a late-stage biopharma company aiming to improve surgical outcomes. Through locally administered, controlled, prolonged-release therapeutics, PolyPid’s proprietary PLEX (Polymer-Lipid Encapsulation matriX) technology pairs with Active Pharmaceutical Ingredients (APIs), enabling precise delivery of drugs at optimal release rates over durations ranging from several days to months. PolyPid’s lead product candidate D-PLEX100 is in Phase 3 clinical trials for the prevention of soft tissue abdominal surgical site infections. In addition, the Company is currently in preclinical stages to test the efficacy of OncoPLEX for treatment of solid tumors, beginning with glioblastoma.

For additional Company information, please visit http://www.polypid.com and follow us on Twitter and LinkedIn.

Contacts: 
PolyPid, Ltd. 
Ori Warshavsky
COO – US Operations
Tel: +1-908-376-6758

Investors:
Brian Ritchie
LifeSci Advisors
212-915-2578
britchie@lifesciadvisors.com


PolyPid Ltd. Ordinary Shares

NASDAQ:PYPD

PYPD Rankings

PYPD Latest News

PYPD Stock Data

22.89M
1.69M
30.08%
39.71%
0.07%
Surgical and Medical Instrument Manufacturing
Manufacturing
Link
United States of America
Petah Tikva

About PYPD

polypid®, a specialty pharmaceutical company, develops and manufactures products based on its plex™ technology. so far, 70 patients have been treated in clinical trials with polypid’s anti-infection products demonstrating safety and efficacy. polypid is in the process of submitting its lead product for phase-iii trial in the us and eu. plex™ is able to optimize drugs'​ therapeutic performance and clinical outcomes. plex™-based protected drug reservoir is implanted directly into the body’s target area thus enabling prolonged delivery of drugs, over periods ranging from days to several months. polypid’s pipeline focuses on 3 products: d-plex™ - intended for prevention and treatment of surgical infections caused by bacteria. its effectiveness is currently being tested in patients undergoing open-heart surgery, with a view to preventing infections that may occur following surgery. the product is currently undergoing clinical studies at several medical centers. bonypid®-1000 - designed to e